Homepage / Portfolio

Portfolio

All
Biotechnology
Medical Technology

CBI has successfully created a diversified portfolio of well-funded biotechnology and medical technology companies. CBI’s portfolio companies develop advanced technologies from the best institutions and minds in Israel and the US, aiming to provide solutions for significant unmet medical needs. CBI and its portfolio companies collaborate with multinational pharmaceutical companies and major investment funds.

Biotechnology Companies by Stage

Company

Pre-Clinical

Phase I

Phase II

Phase III

Market

Biotechnology Companies

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders. This company has been recently acquired by Novartis.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

Medical Technology Companies

+

Sight Diagnostics

Sight Diagnostics uses advanced computer-vision and machine-learning technology in the field of blood diagnostics.
+

Colospan

Colospan is developing novel medical device aiming to alleviate the profound clinical and economic burden of anastomotic leaks following colorectal surgeries.
+

Pi-Cardia

Pi-Cardia is developing a unique minimally invasive treatment for patients with life threatening heart valve disease.
+

FDNA

FDNA operates in the field of genetics, focusing on artificial intelligence-based phenotyping.

SPAC

+

Cactus Acquisition Corp. 1

The Cactus Acquisition Corp. 1 (Nasdaq: CCTSU) is a SPAC focusing on Isareli-related targets in the healthcare business